Identify, Develop, Acquire and Expand
Our Strategy
Our strategy involves maximizing the potential of our existing brands,
while continuing to build a portfolio of differentiated products.
Cumberland is focused on identifying earlier stage product candidates that
have the potential to improve patient care.
Our majority-owned subsidiary, Cumberland Emerging Technologies
(CET) is for just that purpose. We supplement our acquisition and late
stage development initiatives with CET’s early-stage drug development
activities. CET represents a joint initiative between Cumberland
Pharmaceuticals Inc., Vanderbilt University, the state of Tennessee
supported LaunchTN and WinHealth Pharma. The mission of CET is to
identify promising new biomedical products and advance them towards
the marketplace.
At CET we have established a series of collaboration agreements with a
select group of academic research institutions located across the mid
south region of the U.S. We work with our university partners to identify
and establish arrangements for each new product candidate. We then
team with the university scientific team to support product development
and also identify opportunities to secure grant funding.
We also actively pursue opportunities to acquire additional marketed products as well as late-stage development product candidates in our target medical specialties.
Our business development efforts are led by a multi-disciplinary team with
significant pharmaceutical and transactional expertise. We proactively
seek out and evaluate product candidates from a variety of sources,
including our international network of advisors. Highly critical selection
criteria guide our acquisition strategy as we pursue new development
stage assets that fit our medical expertise and commercial capabilities.
We seek proprietary products that provide a differentiated benefit to
patients. In addition, we target products that could benefit from the
promotional capabilities of our sales and marketing organization or that
could be expanded to help new patient groups through the efforts of our
development team.
Where appropriate, Cumberland is poised to acquire and negotiate rights
to those products to support and commercialize them. In acquiring these
already approved products, we are able to add to our growing portfolio to
meet the needs of patients
We believe that exploring opportunities to expand the market potential for
our existing commercial products represents our lowest-risk growth
strategy. Cumberland is continually evaluating new opportunities to
support the patients who can benefit from our products by exploring
potential new indications and designing new product presentations.
The Company focuses on the hospital acute care, gastroenterology and
oncology market segments that feature concentrated prescriber bases.
Our sales and marketing efforts are focused on expanding our reach
within the medical community and keeping health care providers informed
of how our products are able to improve the quality of care for their
patients. The combination of our ongoing development activities and
marketing efforts drives the success of our products.